Global Information
회사소개 | 문의 | 비교리스트

시장 스포트라이트 : 호지킨 림프종

Market Spotlight: Hodgkin´s Lymphoma

리서치사 Datamonitor Healthcare
발행일 2021년 05월 상품코드 939992
페이지 정보 영문 44 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 1,318 ₩ 1,905,000 PDF (Single User License)


시장 스포트라이트 : 호지킨 림프종 Market Spotlight: Hodgkin´s Lymphoma
발행일 : 2021년 05월 페이지 정보 : 영문 44 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 호지킨 림프종 관련 시장을 조사했으며, 질환 배경, 치료법, 역학, 출시되고 있는 의약품, 파이프라인상 의약품, 약사 규제면의 중요 동향, 라이선싱과 자산 인수, 모특허, 매출 기회, 임상시험 상황 등의 정보를 제공하고, 애널리스트 및 업계 리더의 견해도 정리하여 전해드립니다.

목차

개요

주요 조사 결과

질환 배경

  • 아류형

치료법

  • 화학요법
  • 방사선 치료
  • 면역치료
  • 줄기세포 이식(SCT)

역학

출시되고 있는 의약품

파이프라인상 의약품

최신 동향과 애널리스트의 의견

  • Keytruda(2020년 3월 2일)
  • Folotyn(2019년 1월 17일)

향후 주요 동향

규제면의 주요 동향

  • 표준 심사

성공 가능성

라이선싱과 자산 인수 계약

  • BeiGene, Bristol/Celgene 합병전에 Tislelizumab을 재취득

모특허

매출 기회

임상시험 상황

  • 각 단계의 임상시험 의뢰자
  • 각 상의 임상시험 의뢰자

참고 문헌

  • 처방약에 관한 정보

부록

KSA 20.06.18

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 80,800 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028.

In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin's lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.

The approved drugs in the Hodgkin's lymphoma space target antibody-drug conjugate, cluster of differentiation 30/TNFRSF8, microtubules (tubulin), DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.

The greatest proportion of the industry-sponsored drugs in active clinical development for Hodgkin's lymphoma are in Phase II, with no drugs in Phase III.

Therapies in the pipeline for Hodgkin's lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.

The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Hodgkin's lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of Hodgkin's lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the Hodgkin's lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin's lymphoma, with 51 trials.

Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin's lymphoma, followed by Bristol Myers Squibb.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • AFM13 for Hodgkin's Lymphoma (April 9, 2021)
  • Camidanlumab Tesirine for Hodgkin's Lymphoma (December 6, 2020)
  • Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Keytruda for Hodgkin's Lymphoma (March 2, 2020)

KEY REGULATORY EVENTS

  • New Approvals, Biosecurity In Spotlight As China Gears For National Congress

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Daiichi's Novel EZH Candidate Progresses In New Consortium Trial
  • BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of Hodgkin's lymphoma, 2019-28
  • Figure 2: Overview of pipeline drugs for Hodgkin's lymphoma in the US
  • Figure 3: Pipeline drugs for Hodgkin's lymphoma, by company
  • Figure 4: Pipeline drugs for Hodgkin's lymphoma, by drug type
  • Figure 5: Pipeline drugs for Hodgkin's lymphoma, by classification
  • Figure 6: AFM13 for Hodgkin's Lymphoma (April 9, 2021): Phase I - University of Texas
  • Figure 7: Camidanlumab Tesirine for Hodgkin's Lymphoma (December 6, 2020): Phase II - R/R HL
  • Figure 8: Keytruda for Hodgkin's Lymphoma (May 13, 2020): Phase III - KEYNOTE-204
  • Figure 9: Keytruda for Hodgkin's Lymphoma (March 2, 2020): Phase III - KEYNOTE-204
  • Figure 10: Probability of success in the hematologic pipeline
  • Figure 11: Clinical trials in Hodgkin's lymphoma
  • Figure 12: Top 10 drugs for clinical trials in Hodgkin's lymphoma
  • Figure 13: Top 10 companies for clinical trials in Hodgkin's lymphoma
  • Figure 14: Trial locations in Hodgkin's lymphoma
  • Figure 15: Hodgkin's lymphoma trials status
  • Figure 16: Hodgkin's lymphoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of Hodgkin's lymphoma, 2019-28
  • Table 2: Five-year prevalent cases of Hodgkin's lymphoma, 2019-28
  • Table 3: Marketed drugs for Hodgkin's lymphoma
  • Table 4: Pipeline drugs for Hodgkin's lymphoma in the US
  • Table 5: AFM13 for Hodgkin's Lymphoma (April 9, 2021)
  • Table 6: Camidanlumab Tesirine for Hodgkin's Lymphoma (December 6, 2020)
  • Table 7: Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Table 8: Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Table 9: Historical global sales, by drug ($m), 2016-20
  • Table 10: Forecasted global sales, by drug ($m), 2021-25
Back to Top
전화 문의
F A Q